ArticleInvestigational new drugs2025

DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma.

Lu Yang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.